Get started
BAYERBAYERBAYER

BAYER

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

1BAYN trade ideas

Bayer stock : Contrarian storyBayer stock might be considered a contrarian investment: Legal overhang from Monsanto acquisition: The ongoing litigation related to the Roundup herbicide has created significant uncertainty and negatively impacted Bayer's stock price. A contrarian investor might see this as an overreaction and believe the company's long-term value will prevail. Undervalued compared to peers: Some analysts believe Bayer is undervalued compared to its competitors in the pharmaceutical and agricultural industries. This could present an opportunity for contrarian investors who believe the market has overcorrected. Potential for turnaround: Bayer has faced challenges in recent years, but the company is taking steps to address its issues, including restructuring and focusing on innovation. A contrarian investor might bet on the success of these efforts and a future rebound in the stock price. Risks to consider: Uncertainty about the outcome of the Roundup litigation: The potential financial impact of ongoing and future lawsuits remains a significant risk for Bayer. Challenges in the pharmaceutical and agricultural industries: Bayer faces competition and other challenges in its core business segments. Execution risk: There's no guarantee that Bayer's restructuring and innovation efforts will be successful.
XETR:BAYNLong
by StockBlog
Bayer AG Analysis: Growth Potential and Positive Buying SentimenThe history of Bayer AG shares goes through many key moments and events: Foundation and early years: Bayer was founded in 1863 by Friedrich Bayer and Johann Wagner in Germany. The company initially dealt with the production of chemicals and textile dyes. Development of aspirin: In 1897, Bayer synthesized aspirin, which became one of the most recognizable drugs in the world. This is considered one of the key moments that established the profile of the company. World War I: During World War I, most of Bayer's assets were confiscated by the Allies, and the company was forced to reorganize. World War II and post-war period: Bayer, like many German companies, went through significant changes after World War II. A few years later, Bayer joined the newly formed chemical group "Fritz Haber" and focused on innovation. Diversification and Growth: In the 1970s and 1980s, the company began to diversify into areas such as pharmaceuticals, agronomy, and biotechnology. Acquisitions and New Products: Bayer AG acquired companies that strengthened its portfolio, including Monsanto in 2018, which provided significant advances in agronomy. Recent Challenges: In recent years, the company has faced legal challenges and disputes related to its products, particularly glyphosate, the active ingredient in Roundup. Key Points Oakmark International fund manager David Herro sees growth potential for Bayer. The company's agricultural cycle is showing signs of bottoming out. Bayer AG operates in three main segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment focuses on sustainable agriculture through seeds and crop protection. The Pharmaceuticals segment offers prescription products, particularly in the areas of cardiology and women's health. The Consumer Health segment includes nonsteroidal dermatology products and health supplements.
XETR:BAYNLong
by ForexCompany
BAYER AG: $40.60 | Aspirin AlkaSeltzer Monsanto + $11bn Settled Bill Anderson doing the roadshow in Dc and Carlyle Group seems to be going in heavy at current levels or lower for the next RUN UP a long game to make a killing for heavy hitters in the pharma bio agri chemical business the timing to position for such a deal takes time and feel in the this type of business the usual play is Dress up Window PUMP for public retails the rest to participate unload shares and reserve cash to acquire a highly controversial company MONSANTO ROUNUP herbicide with Glycophaste is the EYE SOAR or hang up where litigation is a downgrade for fund managers it settled the 100,000 lawsuits on roundup to $11bn just this October 2023 this is done.. and we begin to DCA slowly and reserve at the buy zone or shakedown levels for next WINDOW DRESSING acquisition of BAYER could be a COViD Vaccine or some super food enhance in the VEGiE MEAT business gaining traction
XETR:BAYN
by senyor
7
Bayer (BAYN): End of a long 9-year correctionBayer (BAYN): XETR:BAYN Upon request from one of our members, we're taking a closer look at Bayer AG. We believe that we are still in an overarching Wave II. This wave finds its last true support at the 88.2% retracement level at €24.51. Falling significantly below this level would likely lead us to see a 100% retracement down to €8.48, which would be severe for a company like Bayer, considering its all-time high was at €144. Observing the chart on a 2-day basis, we note that the Wave 5 extension falls into the zone between 50% and 61.8%, which also includes the 88.2% level. This truly is the last turning point Bayer might have.
XETR:BAYNLong
by freeguy_by_wmc
1
Bayer (BAYN): Is the Bottom Finally Here?Since our initial analysis in November, Bayer's stock has experienced a 40% pullback. Despite missing our limit order by 2%, we have decided to enter the market now and plan to make additional purchases if the price drops further. The stock has held around the 88.2% Fibonacci retracement level. We are currently within the 50-61.8% Fibonacci extension zone for Wave 5, which aligns with our bottom outlook. Our entry strategy involves making an initial purchase now, acknowledging the recent support levels. We plan to add to our position with multiple entries if the price drops further. Our stop-loss is set wide, at an additional 44% below our entry price, to accommodate potential volatility. This is considered a long-term swing trade, with an expectation of significant upward movement once the bottom is confirmed. This could be a knife catch here so please don't cut yourself too deep.
XETR:BAYNLong
by freeguy_by_wmc
GERMANY STOCK > ( BAYN ) long Based on my graphic analysis I observe a bullish projection of 11% in the price of this corporation, that is; from $28.79 it will rise to $31.96. With a sell exit emerging at $26.47, it is worth remembering that exactly how long the rally will take is unpredictable, the market will simply do its job. We can mention that it will happen within the next 15 to 25 days from this post! REFERENCES: * Green line: purchase price: $29.79 * Red line: emerging exit (stop loss) -8% * White goods: profit +11% However, it is important to remember that these marked lines must be respected. If the price drops 3-5% after executing the position, don't try to improvise and change everything. The movement could return to the initial direction and you will be left frustrated! "Sitting calmly and waiting for the development of the operation most of the time will allow you to earn much more money. That is, sit in the stands and enjoy the spectacle that the bull will present to you, control your emotions, since "The biggest enemy to "The time to invest is yourself." As for capital management, I leave it to personal discretion knowing that we must always have money flowing and remain firm in the market. Greetings and I hope you take advantage of this good negotiation opportunity! > Josías Baltazar.n
XETR:BAYNLong
by JARTRADING2
If Germany is the sick man of Europe. #Bayer looking deathlyThe #EU is Marxist, Socialist, and is involved in Price setting That didn't work out too well for USSR as economic powerhouse and so too we see the once great German economy being brought to it's knees. It is being de-industralized and being brought down in a great economic levelling of the union Such a shame Bayer Pharmaceutical is arguably a company we could do without .. so this chart does not upset me too much ... But it is major component of the #DAX and highlights the economic pain that Germany may indeed go through in the next recession.
XETR:BAYNShort
by BallaJi
7
Bayer Cuts Dividends to Reduce DebtIn a strategic move to tackle its mounting debt and enhance financial flexibility, Bayer ( OTC:BAYRY ), the German pharmaceutical giant, has announced a significant shift in its dividend policy. The decision, though met with mixed reactions from investors and analysts, underscores the company's commitment to addressing its pressing financial challenges. Facing High Debt and Challenging Cash Flow: Bayer's ( OTC:BAYRY ) decision to amend its dividend policy stems from a pressing need to mitigate its high debt burden and grapple with a challenging free cash flow situation. Chief Executive Bill Anderson emphasized the company's priority to reduce debt and increase flexibility, acknowledging the necessity of the amended dividend policy in achieving these objectives. A Drastic Reduction in Dividends: The scale of the dividend reduction is striking. From 2.40 euros per share in the previous year, Bayer ( OTC:BAYRY ) now proposes a mere 0.11 euro dividend for 2023. This substantial cut reflects the severity of the financial constraints Bayer is contending with and underscores the urgency with which it seeks to address them. Analyst Insights and Investor Reactions: Analysts at Jefferies have characterized Bayer's move as emblematic of the extensive operational and financial challenges confronting the company. They emphasize the need for further significant strategic actions to rectify the balance sheet and restore investor confidence. Investor reactions have been mixed, with some expressing understanding of the company's predicament, while others voice concerns about the implications for shareholder returns and the long-term health of the business. Strategic Imperatives: Job Cuts and Potential Breakup: Bayer's ( OTC:BAYRY ) dividend policy amendment follows a series of strategic maneuvers aimed at stabilizing its financial position and reigniting growth. In January, the company announced job cuts, signaling a commitment to streamline operations and reduce costs. Moreover, Bayer ( OTC:BAYRY ) has been exploring options to potentially dismantle its diverse portfolio, which includes prescription drugs, consumer health products, crop chemicals, and seeds. This strategic evaluation underscores the company's willingness to undertake bold measures to revitalize its performance and buoy its beleaguered share price. Conclusion: Bayer's ( OTC:BAYRY ) decision to revise its dividend policy represents a pivotal moment in its ongoing efforts to navigate choppy financial waters. As the company grapples with high debt, challenging cash flow dynamics, and analyst scrutiny, its strategic imperatives underscore a commitment to reshaping its business for sustained success. The road ahead may be fraught with challenges, but Bayer's ( OTC:BAYRY ) willingness to confront them head-on signals a determination to emerge stronger and more resilient in the face of adversity.
OTC:BAYRYLong
by DEXWireNews
Bayer: Down the hatch! 🍺After Bayer's stock recently tried to break through the support level of €39.91, it has now made another attempt. Whether the stock succeeds in sustainably breaking below this support level - as envisaged in our primary scenario - or whether it needs further impetus in the form of a corrective upward move is irrelevant for the further course of our expectations. We therefore fully expect a sell-off below this level, as we expect the low of the major wave (II) correction underway since 2015 to be around the 78.60 retracement at €30.84. Only once this low is in place do we see Bayer shares making sustainable gains again.
XETR:BAYNShort
by MarketIntel
1
Why Bayer Stock is a Great Long-Term Investment OpportunityBayer AG is a German multinational pharmaceutical and life sciences company founded in 1863. The company is headquartered in Leverkusen, Germany, and employs over 100,000 people worldwide. Bayer's core business areas are human and veterinary pharmaceuticals, consumer healthcare products, agricultural chemicals, and biotechnology products. Bayer stock is a great long-term investment opportunity for several reasons. The first one is that its stock has created a strong weekly demand level located at around 49 euros per share. This should be enough reason to buy Bayer AG stock shares. Secondly, the company has a strong history of financial stability and profitability. In addition, Bayer has a diversified product portfolio with exposure to many different industries. Bayer is committed to innovation and has a strong R&D pipeline. Bayer AG is a publicly traded company with shares that trade on the Frankfurt Stock Exchange, and the company has a market capitalization of over €51 billion. The company's stock has not performed well in recent years, losing more than 70% of its value since up more than 50% since 2016. It's now a great opportunity to buy shares of Bayer AG stock. There is a lot of profit potential with room to reach €88 per share and higher.
XETR:BAYNLong
by AlfonsoMoreno
Bayer AG (BAYN.de) bullish scenario:The technical figure Falling Wedge can be found in the daily chart in the German company Bayer AG (BAYN.de). Bayer AG is a German multinational pharmaceutical and biotechnology company and one of the largest pharmaceutical companies in the world. Headquartered in Leverkusen, Bayer's areas of business include pharmaceuticals; consumer healthcare products, agricultural chemicals, seeds and biotechnology products. The Falling Wedge broke through the resistance line on 22/03/2023. If the price holds above this level, you can have a possible bullish price movement with a forecast for the next 9 days towards 60.750 EUR. According to experts, your stop-loss order should be placed at 54.890 EUR if you decide to enter this position. Bayer AG plans to spend $1 billion on drug research and development in the U.S. this year as it works to double its sales in the country by the end of the decade, Bayer's top U.S. pharmaceutical executive told Reuters. Sebastian Guth, president of Bayer's pharmaceuticals business in the Americas, in an interview with Reuters, said the company increased U.S. employees working on marketing for its pharmaceutical business by around 50% over the last three years and plans to expand on that by another 75% by 2030. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals and cannot be held liable nor guarantee any profits or losses.
XETR:BAYNLong
by legacyFXofficial
Bayer continues to hold back the bulls.Bayer AG - 30d expiry - We look to Sell at 54.48 (stop at 56.11) Daily signals are bearish. 54.50 continues to hold back the bulls. Bespoke resistance is located at 54.50. Preferred trade is to sell into rallies. The bearish engulfing candle on the daily chart is negative for sentiment. Our profit targets will be 50.41 and 49.41 Resistance: 52.00 / 53.20 / 54.50 Support: 49.50 / 48.50 / 47.00 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis , like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis , as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
XETR:BAYNShort
by Saxo